查看購物車
  • English
  • Japanese
全球寡核苷酸CDMO市場（至2031年）：按服務（契約製造（臨床和商業）及研發）、類型（ASO和siRNA）、應用（治療、研究和診斷）、最終用戶（製藥和生物技術）、地區和競爭對手分類
市場調查報告書
商品編碼
2130448

全球寡核苷酸CDMO市場（至2031年）：按服務（契約製造（臨床和商業）及研發）、類型（ASO和siRNA）、應用（治療、研究和診斷）、最終用戶（製藥和生物技術）、地區和競爭對手分類

Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA), Application (Therapeutic, Research, Diagnostics), End User (Pharma, Biotech), Region, Competition - Global Forecast to 2031
出版日期: | 出版商: MarketsandMarkets | 英文 316 Pages | 訂單完成後即時交付

價格

預計寡核苷酸 CDMO 市場將從 2026 年的 38.8 億美元成長到 2031 年的 111.4 億美元，預測期內複合年成長率為 23.5%。

隨著製藥和生技公司為支持其不斷成長的寡核苷酸開發平臺而增加開發和生產的外包，寡核苷酸CDMO市場正在擴張。此外，隨著專案從臨床階段推進到商業化階段，與CDMO建立更多合作夥伴關係以實現規模化生產，也推動了對製程開發、合成、純化、分析測試和GMP生產的需求。申辦方越來越傾向於選擇擁有靈活生產能力和綜合專業知識的CDMO，以支持其從研發到商業化生產的整個過程。

調查範圍
調查期 2026-2031
基準年 2025
預測期 2026-2031
單元 金額（美元）
部分 服務類型、類型、應用程式、最終用戶
目標區域 北美洲、歐洲、亞太地區、拉丁美洲、中東、非洲

然而，治療性寡核苷酸生產的複雜性仍然是一個主要的阻礙因素。序列延長、化學修飾和偶聯都會增加合成和純化的難度。此外，在整個放大過程中保持品質的一致性需要專用設備、經過驗證的工藝和熟練的人員。因此，擁有可擴展基礎設施和強大分析能力的合約研發生產機構（CDMO）更有能力支援複雜的寡核苷酸開發專案。

寡核苷酸CDMO市場-IMG1

“預計在預測期內，反義寡核苷酸領域將以最高的複合年成長率成長。”

受反義寡核苷酸 (ASO) 療法研發的擴張和生產外包趨勢的推動，預計 ASO 細分市場將在寡核苷酸 CDMO 市場中實現最高的複合年成長率 (CAGR)。 ASO 研發專案需要專業的合成、純化、分析測試和 GMP 生產能力。隨著 ASO 候選藥物進入臨床開發階段，擴充性且可靠的 CDMO 服務的需求不斷成長。分子結構的日益複雜也促使製藥和生物技術公司將製造外包給專業供應商。預計在整個預測期內，這些因素將進一步增強對支持 ASO 研發的寡核苷酸 CDMO 服務的需求。

“按應用領域來看，治療領域預計將成長最快。”

預計在寡核苷酸類藥物研發的擴張和生產外包的日益普及的推動下，治療應用領域將成為市場中複合年成長率最高的領域。治療藥物研發專案需要合成、純化、分析測試和GMP生產等專業服務。隨著ASO、siRNA和其他寡核苷酸候選化合物的臨床開發不斷推進，對擴充性且符合規範的生產服務的需求也不斷成長。此外，分子複雜性的日益增加進一步推動了製藥和生物技術公司對專業CDMO的依賴。這些因素表明，在預測期內，對支持治療應用的CDMO服務的需求將進一步成長。

“預計美國在預測期內將錄得最高的複合年成長率。”

預計美國將錄得最高的複合年成長率，這主要得益於眾多擁有活躍寡核苷酸開發平臺的製藥和生物技術公司在美國的集中佈局。成熟的合約研發生產（CDMO）基礎設施以及在寡核苷酸合成、純化、分析測試和GMP生產方面的專業能力，進一步推動了市場成長。對臨床和商業化生產能力的需求不斷成長，也進一步促進了生產外包。反義寡核苷酸（ASO）、小干擾RNA（siRNA）和其他寡核苷酸計畫的進展，推動了可擴展生產和專業製程開發的需求。預計這些因素將在整個預測期內持續推動美國寡核苷酸CDMO市場的擴張。

本報告檢視了全球寡核苷酸 CDMO 市場，提供了市場概述、影響市場成長的各種因素分析、技術和專利趨勢、法律制度、案例研究、歷史和預測的市場規模、按各個細分市場和地區/主要國家/地區進行的詳細分析、競爭格局以及主要公司的概況。

目錄

第1章：引言

第2章執行摘要

第3章重要考察

第4章 市場概覽

  • 市場動態
    • 促進因素
    • 抑制因子
    • 機會
    • 任務
  • 未滿足的需求和閒置頻段
  • 與相關市場和不同產業相關的跨領域機遇
  • 一級/二級/三級公司的策略性舉措

第5章 產業趨勢

  • 波特五力分析
  • 宏觀經濟展望
    • GDP趨勢與預測
    • 全球醫療保健產業趨勢
    • 全球生技產業的發展趨勢
  • 價值鏈分析
  • 生態系分析
  • 2026-2027 年主要會議和活動
  • 影響客戶業務的趨勢/顛覆性因素
  • 投資和資金籌措場景
  • 2025年美國關稅對寡核苷酸CDMO市場的影響

第6章：技術進步、人工智慧的影響、專利、創新與未來應用

  • 技術分析
    • 主要技術
    • 互補技術
    • 鄰近技術
  • 技術藍圖
  • 未來應用
  • 人工智慧/生成式人工智慧對枕葉寡核苷酸CDMO市場的影響

第7章永續性和監管情勢

  • 當地法規和合規性
  • 對永續性的承諾
  • 監理政策對永續性舉措的影響
  • 認證、標籤檢視、環境標準

第8章：顧客趨勢與購買行為

  • 決策流程
  • 相關人員及購買評估標準
  • 實施障礙和內部挑戰
  • 各個終端用戶產業尚未滿足的需求

第9章 寡核苷酸CDMO市場：依服務類型分類

  • 契約製造
    • 商業化階段
    • 臨床階段
  • 合約開發
  • 其他

第10章 寡核苷酸CDMO市場：依應用領域分類

  • 治療
  • 研究
  • 診斷

第11章 寡核苷酸CDMO市場：按類型分類

  • 反義寡核苷酸（ASO）
  • 小干擾RNA（siRNA）
  • 其他

第12章 寡核苷酸CDMO市場：依最終用戶分類

  • 製藥和生物技術公司
  • 診斷公司
  • 其他

第13章 寡核苷酸CDMO市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東
    • GCC
    • 其他
  • 非洲

第14章 競爭格局

  • 主要參與企業的策略/優勢
  • 收入分析
  • 市佔率分析
  • 公司估值矩陣：主要公司（寡核苷酸CDMO市場）
  • 公司估值矩陣：新創企業/中小企業
  • 競爭格局
  • 品牌/產品比較分析
  • 企業估值和財務指標

第15章：公司簡介

  • 大公司
    • BACHEM INC.
    • THERMO FISHER SCIENTIFIC INC.
    • AGILENT TECHNOLOGIES, INC.
    • WUXI APPTEC
    • MARAVAI LIFESCIENCES
    • LONZA
    • EUROFINS SCIENTIFIC
    • DANAHER CORPORATION
    • GENSCRIPT
    • SYNGENE INTERNATIONAL LIMITED
    • EUROAPI
    • AJINOMOTO CO., INC.
    • ST PHARM
    • KANEKA CORPORATION
    • POLYPEPTIDE GROUP
    • AURIGENE PHARMACEUTICAL SERVICES LTD.
    • BIOSPRING
    • NIPPON SHOKUBAI CO., LTD.
    • LGC BIOSEARCH TECHNOLOGIES
  • 其他公司
    • OLIGO FACTORY
    • CORDEN PHARMA
    • BIO-SYNTHESIS, INC.
    • MICROSYNTH
    • SYNOLIGO BIOTECHNOLOGIES, INC.
    • HONGENE BIOTECH CORPORATION
    • SYLENTIS, SA
    • CREATIVE BIOGENE
    • NITTO AVECIA
    • NJ BIO, INC.

第16章調查方法

第17章附錄

Product Code: BT 9273

The oligonucleotide CDMO market is expected to reach USD 11.14 billion in 2031, up from USD 3.88 billion in 2026, at a CAGR of 23.5% over the forecast period. The oligonucleotide CDMO market is expanding as pharmaceutical and biotechnology companies increasingly outsource development and manufacturing to support growing oligonucleotide pipelines. Growing CDMO partnerships to enable scalability are driving demand for process development, synthesis, purification, analytical testing, and GMP manufacturing as programs advance toward clinical and commercial stages. Sponsors are increasingly seeking CDMOs with flexible capacity and integrated capabilities to support development through commercial manufacturing.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsService Type, Type, Application, and End User
Regions coveredNorth America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa

However, the complexities of therapeutic oligonucleotide manufacturing remain a key restraint. Longer sequences, chemical modifications, and conjugation can increase synthesis and purification challenges. Maintaining consistent quality during scale-up also requires specialized equipment, validated processes, and skilled personnel. Consequently, CDMOs with scalable infrastructure and strong analytical capabilities are better positioned to support complex oligonucleotide programs.

Oligonucleotide CDMO Market - IMG1

"Antisense oligonucleotides segment is expected to grow at the highest CAGR during the forecast period"

The antisense oligonucleotide (ASO) segment is projected to grow at the highest CAGR in the oligonucleotide CDMO market, driven by expanding development of ASO-based therapeutics and increased outsourcing of manufacturing. ASO programs require specialized synthesis, purification, analytical testing, and GMP manufacturing capabilities. The advancement of ASO candidates through clinical development is increasing demand for scalable and reliable CDMO services. Rising molecular complexity is also prompting pharmaceutical and biotechnology companies to outsource manufacturing to specialized providers. These factors are expected to strengthen demand for oligonucleotide CDMO services supporting ASO development over the forecast period.

"Therapeutic applications segment to grow fastest"

The therapeutic applications segment is projected to grow at the highest CAGR in the oligonucleotide CDMO market, driven by expanding development of oligonucleotide-based therapeutics and increased outsourcing of manufacturing. Therapeutic programs require specialized services for synthesis, purification, analytical testing, and GMP manufacturing. The advancement of ASO, siRNA, and other oligonucleotide candidates through clinical development is increasing demand for scalable, regulatory-compliant manufacturing. Rising molecular complexity is further encouraging pharmaceutical and biotechnology companies to rely on specialized CDMOs. These factors are expected to strengthen demand for CDMO services supporting therapeutic applications during the forecast period.

"US is expected to grow at the highest CAGR during the forecast period"

The US is expected to post the highest CAGR in the oligonucleotide CDMO market, driven by a strong concentration of pharmaceutical and biotechnology companies with active oligonucleotide development pipelines. Established CDMO infrastructure and specialized capabilities in oligonucleotide synthesis, purification, analytical testing, and GMP manufacturing further support market growth. Rising demand for clinical and commercial manufacturing capacity is also strengthening outsourcing activity. Advancements in ASO, siRNA, and other oligonucleotide programs are driving demand for scalable manufacturing and specialized process development. These factors are expected to support continued expansion of the US oligonucleotide CDMO market over the forecast period.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side - 70% and Demand Side- 30%
  • By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives - 25%
  • By Region: North America - 40%, Europe - 25%, Asia Pacific - 25%, Latin America - 5%, the Middle East & Africa - 5%

Bachem (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), WuXi AppTec (China), Maravai LifeSciences (US), Lonza (Switzerland), Eurofins Scientific (Luxembourg), Danaher Corporation (US), GenScript (US), Syngene International Limited (India), Ajinomoto Co., Inc. (Japan), EUROAPI (France), ST Pharm (South Korea), Kaneka Corporation (Japan), PolyPeptide Group (Switzerland), Aurigene Pharmaceutical Services Ltd. (India), BioSpring (Germany), Nippon Shokubai Co., Ltd. (Japan), LGC Biosearch Technologies (UK), Oligo Factory (US), Corden Pharma (Switzerland), Bio-Synthesis, Inc. (US), Microsynth (Switzerland), Synoligo Biotechnologies, Inc. (US), Hongene Biotech Corporation (China), Sylentis, S.A. (Spain), Creative Biogene (US), Nitto Avecia (US), and NJ Bio, Inc. (US) are key companies providing oligonucleotide CDMO services.

Research Coverage

This research report categorizes the oligonucleotide CDMO market by service type (contract manufacturing {commercial stage, clinical stage}, contract development, and other services {analytical testing, analytical method development & validation, and standalone fill-finish services}), by type (antisense oligonucleotides, small interfering RNA, and other oligonucleotides), by application (therapeutic applications, research applications, and diagnostic applications), by end user (pharmaceutical & biotechnology companies, diagnostic companies, and other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report's scope encompasses detailed information on the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the oligonucleotide CDMO market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, service portfolios, key strategies, service expansions, acquisitions, and recent developments related to the oligonucleotide CDMO market. This report also includes a competitive analysis of emerging startups in the oligonucleotide CDMO industry ecosystem.

Key Benefits of Buying the Report

The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and provide information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

  • Analysis of key drivers (Growing demand for pre-clinical-to-commercial oligo CDMOs, Increase in CDMO partnerships for scalability, Increasing focus on precision/personalized medicine), restraints (Complexities associated with therapeutic oligonucleotide manufacturing), opportunities (Increasing use of oligos in CRISPR-Cas9 applications, Growing demand for complex and modified oligonucleotides), and challenges (Lack of sustainable supply chain, Limited scalability of GMP oligonucleotide synthesis) influencing the market growth
  • Service Development/Innovation: Detailed insights into newly launched services and innovations in the oligonucleotide CDMO market
  • Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the oligonucleotide CDMO market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and services of leading players, Bachem (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), WuXi AppTec (China), and ST Pharm (South Korea), among others, for the oligonucleotide CDMO market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION AND REGIONS COVERED
    • 1.3.2 YEARS CONSIDERED
    • 1.3.3 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS IN OLIGONUCLEOTIDES CDMO MARKET
  • 2.4 HIGH-GROWTH SEGMENTS
  • 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 OLIGONUCLEOTIDE CDMO MARKET OVERVIEW
  • 3.2 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE
  • 3.3 OLIGONUCLEOTIDE CDMO MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 3.4 OLIGONUCLEOTIDE CDMO MARKET SHARE, BY SERVICE TYPE, 2026 VS. 2031

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Growing demand for Pre-Clinical-to-Commercial oligo CDMOs
      • 4.2.1.2 Increase in CDMO partnerships for scalability
      • 4.2.1.3 Increasing focus on precision/personalized medicine
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 Complexities associated with therapeutic oligonucleotide manufacturing
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Increasing use of oligos in CRISPR-Cas9 applications
      • 4.2.3.2 Expansion of oligonucleotide therapeutics into cardiometabolic and common chronic diseases
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Lack of sustainable supply chain
      • 4.2.4.2 Limited scalability of GMP oligonucleotide synthesis
  • 4.3 UNMET NEEDS AND WHITE SPACES
  • 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.1.2 BARGAINING POWER OF SUPPLIERS
    • 5.1.3 BARGAINING POWER OF BUYERS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 THREAT OF NEW ENTRANTS
  • 5.2 MACROECONOMIC OUTLOOK
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS AND FORECAST
    • 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
    • 5.2.4 TRENDS IN GLOBAL BIOTECH INDUSTRY
  • 5.3 VALUE CHAIN ANALYSIS
  • 5.4 ECOSYSTEM ANALYSIS
    • 5.4.1 ROLE OF PLAYERS IN ECOSYSTEM
  • 5.5 KEY CONFERENCES & EVENTS, 2026-2027
  • 5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.7 INVESTMENT & FUNDING SCENARIO
  • 5.8 IMPACT OF 2025 US TARIFF ON OLIGONUCLEOTIDE CDMO MARKET
    • 5.8.1 INTRODUCTION
    • 5.8.2 KEY TARIFF RATES
    • 5.8.3 PRICE IMPACT ANALYSIS
    • 5.8.4 IMPACT ON COUNTRY/REGION
      • 5.8.4.1 US
      • 5.8.4.2 Europe
      • 5.8.4.3 Asia Pacific
    • 5.8.5 IMPACT ON END-USE INDUSTRIES
      • 5.8.5.1 Pharmaceutical & Biotechnology Companies
      • 5.8.5.2 Diagnostic companies
      • 5.8.5.3 Other end users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 TECHNOLOGY ANALYSIS
    • 6.1.1 KEY TECHNOLOGIES
      • 6.1.1.1 Process technologies
        • 6.1.1.1.1 Solid-phase synthesis
        • 6.1.1.1.2 Liquid-phase synthesis
        • 6.1.1.1.3 Enzymatic phase synthesis
      • 6.1.1.2 Purification, analysis, and quality control technologies
        • 6.1.1.2.1 Affinity chromatography
        • 6.1.1.2.2 Tangential flow filtration (tff) & ultrafiltration
    • 6.1.2 COMPLEMENTARY TECHNOLOGIES
      • 6.1.2.1 Polymerase chain reaction (PCR)
      • 6.1.2.2 Next-generation sequencing (NGS)
      • 6.1.2.3 Microarray technology/hybridization-based assays
    • 6.1.3 ADJACENT TECHNOLOGIES
      • 6.1.3.1 Galnac conjugation/Antibody-oligonucleotide conjugation
      • 6.1.3.2 Lipid nanoparticle (LNP) encapsulation
  • 6.2 TECHNOLOGY ROADMAP
  • 6.3 FUTURE APPLICATIONS
  • 6.4 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET
    • 6.4.1 TOP USE CASES AND MARKET POTENTIAL
    • 6.4.2 BEST PRACTICES IN AI-ENABLED OLIGONUCLEOTIDE CDMO WORKFLOWS
    • 6.4.3 CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE CDMO MARKET
    • 6.4.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
    • 6.4.5 CLIENTS' READINESS TO ADOPT AI-INTEGRATED OLIGONUCLEOTIDE CDMO TECHNOLOGIES

7 SUSTAINABILITY AND REGULATORY LANDSCAPE

  • 7.1 REGIONAL REGULATIONS AND COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.2 INDUSTRY STANDARDS
      • 7.1.2.1 North America
      • 7.1.2.2 Europe
      • 7.1.2.3 Asia Pacific
      • 7.1.2.4 Rest of the World
  • 7.2 SUSTAINABILITY INITIATIVES
  • 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
  • 7.4 CERTIFICATIONS, LABELING, ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 KEY BUYING CRITERIA, BY END USER
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

9 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE

  • 9.1 INTRODUCTION
  • 9.2 CONTRACT MANUFACTURING
    • 9.2.1 COMMERCIAL STAGE
      • 9.2.1.1 Advancing oligonucleotide therapies and demand for reliable commercial-scale GMP supply are driving growth in commercial-stage services
    • 9.2.2 CLINICAL STAGE
      • 9.2.2.1 Advancing clinical pipelines and demand for specialized scalable manufacturing are driving growth in clinical-stage services
  • 9.3 CONTRACT DEVELOPMENT
    • 9.3.1 INCREASINGLY COMPLEX OLIGONUCLEOTIDE PIPELINES AND DEMAND FOR OPTIMIZED CLINICAL MANUFACTURING PROCESSES ARE DRIVING CONTRACT DEVELOPMENT GROWTH
  • 9.4 OTHER SERVICES
    • 9.4.1 INCREASING MOLECULAR COMPLEXITY AND DEMAND FOR INTEGRATED ANALYTICAL AND DRUG-PRODUCT SUPPORT ARE DRIVING GROWTH IN OTHER SERVICES

10 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION

  • 10.1 INTRODUCTION
  • 10.2 THERAPEUTIC APPLICATIONS
    • 10.2.1 EXPANDING THERAPEUTIC APPLICATIONS AND ADVANCING OLIGONUCLEOTIDE PIPELINES ARE DRIVING DEMAND FOR SPECIALIZED CDMO SERVICES.
  • 10.3 RESEARCH APPLICATIONS
    • 10.3.1 EXPANDING GENOMICS, SEQUENCING, CRISPR RESEARCH, AND OUTSOURCED CUSTOM SYNTHESIS DRIVE GROWTH
  • 10.4 DIAGNOSTIC APPLICATIONS
    • 10.4.1 EXPANDING MOLECULAR DIAGNOSTICS AND PRECISION ONCOLOGY DRIVE DEMAND FOR SPECIALIZED OLIGONUCLEOTIDE MANUFACTURING

11 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE

  • 11.1 INTRODUCTION
  • 11.2 ANTISENSE OLIGONUCLEOTIDE (ASO)
    • 11.2.1 ADVANCING ASO PIPELINES AND INCREASING DEMAND FOR SCALABLE GMP MANUFACTURING ARE DRIVING GROWTH
  • 11.3 SMALL INTERFERING RNA (SIRNA)
    • 11.3.1 EXPANDING SIRNA PIPELINES AND INCREASING DEMAND FOR SPECIALIZED GMP MANUFACTURING ARE DRIVING GROWTH IN THE MARKET.
  • 11.4 OTHER OLIGONUCLEOTIDES
    • 11.4.1 EXPANDING CRISPR AND TARGETED APTAMER APPLICATIONS DRIVE DEMAND FOR SPECIALIZED OLIGONUCLEOTIDE CDMO CAPABILITIES

12 OLIGONUCLEOTIDE CDMO MARKET, BY END USER

  • 12.1 INTRODUCTION
  • 12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 12.2.1 EXPANDING NUCLEIC ACID PIPELINES AND INCREASING OUTSOURCING DRIVE PHARMACEUTICAL AND BIOTECHNOLOGY DEMAND FOR CDMO SERVICES
  • 12.3 DIAGNOSTIC COMPANIES
    • 12.3.1 RISING MOLECULAR TESTING AND DEMAND FOR COMPLIANT CUSTOM OLIGOS DRIVE DIAGNOSTIC OUTSOURCING
  • 12.4 OTHER END USERS

13 OLIGONUCLEOTIDE CDMO MARKET, BY REGION

  • 13.1 INTRODUCTION
  • 13.2 NORTH AMERICA
    • 13.2.1 US
      • 13.2.1.1 Expanding domestic GMP capacity and increasing outsourcing are driving US oligonucleotide CDMO growth.
    • 13.2.2 CANADA
      • 13.2.2.1 Integrated North American manufacturing networks and growing outsourcing demand are supporting Canada's oligonucleotide CDMO market
  • 13.3 EUROPE
    • 13.3.1 GERMANY
      • 13.3.1.1 Expanding GMP capacity and integrated oligonucleotide partnerships are driving Germany's market growth
    • 13.3.2 UK
      • 13.3.2.1 Strengthening domestic nucleic-acid infrastructure and growing outsourcing demand are driving UK oligonucleotide CDMO growth
    • 13.3.3 FRANCE
      • 13.3.3.1 Strengthening nucleic-acid capabilities and growing outsourcing demand are driving France's oligonucleotide CDMO market
    • 13.3.4 ITALY
      • 13.3.4.1 Specialized oligonucleotide infrastructure and growing demand for integrated development services are supporting Italy's market growth
    • 13.3.5 SPAIN
      • 13.3.5.1 Expanding domestic manufacturing infrastructure and institutional support for therapeutic oligonucleotides are driving Spain's market growth
    • 13.3.6 REST OF EUROPE
  • 13.4 ASIA PACIFIC
    • 13.4.1 CHINA
      • 13.4.1.1 Expanding integrated manufacturing capacity and strengthening domestic oligonucleotide supply chains are driving China's market growth
    • 13.4.2 JAPAN
      • 13.4.2.1 Advanced manufacturing capabilities and rising demand for complex oligonucleotide therapeutics are driving Japan's market growth
    • 13.4.3 INDIA
      • 13.4.3.1 Expanding GMP infrastructure and global outsourcing are driving India's oligonucleotide CDMO market
    • 13.4.4 AUSTRALIA
      • 13.4.4.1 Expanding domestic manufacturing and growing biopharmaceutical outsourcing are supporting Australia's oligonucleotide CDMO market
    • 13.4.5 SOUTH KOREA
      • 13.4.5.1 Synthetic biology, organoid-based screening, and AI-enabled discovery to support market growth
    • 13.4.6 REST OF ASIA PACIFIC
  • 13.5 LATIN AMERICA
    • 13.5.1 BRAZIL
      • 13.5.1.1 Infectious-disease research, shared protein-production infrastructure, and vaccine innovation to drive market
    • 13.5.2 MEXICO
      • 13.5.2.1 Nearshoring and expanding regional manufacturing capabilities are supporting Mexico's oligonucleotide CDMO market
    • 13.5.3 REST OF LATIN AMERICA
  • 13.6 MIDDLE EAST
    • 13.6.1 GCC
      • 13.6.1.1 Saudi Arabia
        • 13.6.1.1.1 Biotechnology localization and expanding genomic medicine capabilities are driving Saudi Arabia's oligonucleotide CDMO market
      • 13.6.1.2 UAE
        • 13.6.1.2.1 Growing biopharmaceutical activity and need for localized advanced-therapy manufacturing are creating opportunities for UAE's oligonucleotide CDMO services
      • 13.6.1.3 Rest of GCC Countries
    • 13.6.2 REST OF MIDDLE EAST
  • 13.7 AFRICA
    • 13.7.1 GROWING GENOMICS ACTIVITY AND LIMITED LOCAL MANUFACTURING CAPACITY ARE CREATING OPPORTUNITIES FOR OLIGONUCLEOTIDE CDMO SERVICES ACROSS AFRICA

14 COMPETITIVE LANDSCAPE

  • 14.1 INTRODUCTION
  • 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 14.2.1 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE CDMO MARKET, 2023-2026
  • 14.3 REVENUE ANALYSIS
  • 14.4 MARKET SHARE ANALYSIS
  • 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE CDMO MARKET), 2025
    • 14.5.1 STARS
    • 14.5.2 EMERGING LEADERS
    • 14.5.3 PERVASIVE PLAYERS
    • 14.5.4 PARTICIPANTS
  • 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 14.6.1 PROGRESSIVE COMPANIES
    • 14.6.2 RESPONSIVE COMPANIES
    • 14.6.3 DYNAMIC COMPANIES
    • 14.6.4 STARTING BLOCKS
    • 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
  • 14.7 COMPETITIVE SCENARIO
    • 14.7.1 PRODUCT APPROVALS
  • 14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 14.9 COMPANY VALUATION AND FINANCIAL METRICS
    • 14.9.1 COMPANY VALUATION AND FINANCIAL METRICS FOR OLIGONUCLEOTIDE CDMO PLAYERS

15 COMPANY PROFILES

  • 15.1 KEY PLAYERS
    • 15.1.1 BACHEM INC.
      • 15.1.1.1 Business overview
      • 15.1.1.2 Services offered
      • 15.1.1.3 Recent developments
        • 15.1.1.3.1 Product/Service launches
        • 15.1.1.3.2 Expansions
      • 15.1.1.4 MnM view
        • 15.1.1.4.1 Key strengths
        • 15.1.1.4.2 Strategic choices
        • 15.1.1.4.3 Weaknesses and competitive threats
    • 15.1.2 THERMO FISHER SCIENTIFIC INC.
      • 15.1.2.1 Business overview
      • 15.1.2.2 Services offered
      • 15.1.2.3 Recent developments
        • 15.1.2.3.1 Product/Service launches
        • 15.1.2.3.2 Expansions
      • 15.1.2.4 MnM view
        • 15.1.2.4.1 Key strengths
        • 15.1.2.4.2 Strategic choices
        • 15.1.2.4.3 Weaknesses and competitive threats
    • 15.1.3 AGILENT TECHNOLOGIES, INC.
      • 15.1.3.1 Business overview
      • 15.1.3.2 Services offered
      • 15.1.3.3 Recent developments
        • 15.1.3.3.1 Product/Service launches
        • 15.1.3.3.2 Deals
        • 15.1.3.3.3 Expansions
      • 15.1.3.4 MnM view
        • 15.1.3.4.1 Key strengths
        • 15.1.3.4.2 Strategic choices
        • 15.1.3.4.3 Weaknesses and competitive threats
    • 15.1.4 WUXI APPTEC
      • 15.1.4.1 Business overview
      • 15.1.4.2 Services offered
      • 15.1.4.3 Recent developments
        • 15.1.4.3.1 Expansions
      • 15.1.4.4 MnM view
        • 15.1.4.4.1 Key strengths/Right to win
        • 15.1.4.4.2 Strategic choices made
        • 15.1.4.4.3 Weaknesses and competitive threats
    • 15.1.5 MARAVAI LIFESCIENCES
      • 15.1.5.1 Business overview
      • 15.1.5.2 Services offered
      • 15.1.5.3 Recent developments
        • 15.1.5.3.1 Deals
    • 15.1.6 LONZA
      • 15.1.6.1 Business overview
      • 15.1.6.2 Services offered
      • 15.1.6.3 Recent developments
        • 15.1.6.3.1 Deals
        • 15.1.6.3.2 Expansions
    • 15.1.7 EUROFINS SCIENTIFIC
      • 15.1.7.1 Business overview
      • 15.1.7.2 Services offered
      • 15.1.7.3 Recent developments
        • 15.1.7.3.1 Expansions
    • 15.1.8 DANAHER CORPORATION
      • 15.1.8.1 Business overview
      • 15.1.8.2 Services offered
      • 15.1.8.3 Recent developments
        • 15.1.8.3.1 Expansions
        • 15.1.8.3.2 Other Developments
    • 15.1.9 GENSCRIPT
      • 15.1.9.1 Business overview
      • 15.1.9.2 Services offered
      • 15.1.9.3 Recent developments
        • 15.1.9.3.1 Expansions
    • 15.1.10 SYNGENE INTERNATIONAL LIMITED
      • 15.1.10.1 Business overview
      • 15.1.10.2 Services offered
      • 15.1.10.3 Recent developments
        • 15.1.10.3.1 Product/Service launches
        • 15.1.10.3.2 Expansions
    • 15.1.11 EUROAPI
      • 15.1.11.1 Business overview
      • 15.1.11.2 Services offered
      • 15.1.11.3 Recent developments
        • 15.1.11.3.1 Deals
        • 15.1.11.3.2 Expansions
    • 15.1.12 AJINOMOTO CO., INC.
      • 15.1.12.1 Business overview
      • 15.1.12.2 Services offered
      • 15.1.12.3 Recent developments
        • 15.1.12.3.1 Expansions
        • 15.1.12.3.2 Deals
    • 15.1.13 ST PHARM
      • 15.1.13.1 Business overview
      • 15.1.13.2 Services offered
      • 15.1.13.3 Recent developments
        • 15.1.13.3.1 Expansions
        • 15.1.13.3.2 Deals
      • 15.1.13.4 MnM view
        • 15.1.13.4.1 Key strengths
        • 15.1.13.4.2 Strategic choices
        • 15.1.13.4.3 Weaknesses and competitive threats
    • 15.1.14 KANEKA CORPORATION
      • 15.1.14.1 Business overview
      • 15.1.14.2 Services offered
    • 15.1.15 POLYPEPTIDE GROUP
      • 15.1.15.1 Business overview
      • 15.1.15.2 Services offered
      • 15.1.15.3 Recent developments
        • 15.1.15.3.1 Expansions
    • 15.1.16 AURIGENE PHARMACEUTICAL SERVICES LTD.
      • 15.1.16.1 Business overview
      • 15.1.16.2 Services offered
    • 15.1.17 BIOSPRING
      • 15.1.17.1 Business overview
      • 15.1.17.2 Services offered
      • 15.1.17.3 Recent developments
        • 15.1.17.3.1 Service approvals
        • 15.1.17.3.2 Expansions
    • 15.1.18 NIPPON SHOKUBAI CO., LTD.
      • 15.1.18.1 Business overview
      • 15.1.18.2 Services offered
      • 15.1.18.3 Recent developments
        • 15.1.18.3.1 Service launch
        • 15.1.18.3.2 Expansions
    • 15.1.19 LGC BIOSEARCH TECHNOLOGIES
      • 15.1.19.1 Business overview
      • 15.1.19.2 Services offered
      • 15.1.19.3 Recent developments
        • 15.1.19.3.1 Service launch
        • 15.1.19.3.2 Deals
        • 15.1.19.3.3 Expansions
  • 15.2 OTHER PLAYERS
    • 15.2.1 OLIGO FACTORY
    • 15.2.2 CORDEN PHARMA
    • 15.2.3 BIO-SYNTHESIS, INC.
    • 15.2.4 MICROSYNTH
    • 15.2.5 SYNOLIGO BIOTECHNOLOGIES, INC.
    • 15.2.6 HONGENE BIOTECH CORPORATION
    • 15.2.7 SYLENTIS, S.A.
    • 15.2.8 CREATIVE BIOGENE
    • 15.2.9 NITTO AVECIA
    • 15.2.10 NJ BIO, INC.

16 RESEARCH METHODOLOGY

  • 16.1 RESEARCH DATA
    • 16.1.1 SECONDARY DATA
      • 16.1.1.1 Key data from secondary sources
    • 16.1.2 PRIMARY DATA
      • 16.1.2.1 Key data from primary sources
      • 16.1.2.2 Key primary participants
      • 16.1.2.3 Breakdown of primary interviews
      • 16.1.2.4 Key industry insights
  • 16.2 MARKET SIZE ESTIMATION
    • 16.2.1 GLOBAL OLIGONUCLEOTIDE CDMO MARKET ESTIMATION, 2025
    • 16.2.2 SEGMENTAL MARKET SIZE ESTIMATION
  • 16.3 MARKET GROWTH RATE PROJECTIONS
  • 16.4 DATA TRIANGULATION
  • 16.5 FACTOR ANALYSIS
  • 16.6 RESEARCH ASSUMPTIONS
  • 16.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT

17 APPENDIX

  • 17.1 DISCUSSION GUIDE
  • 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 17.3 CUSTOMIZATION OPTIONS
  • 17.4 RELATED REPORTS
  • 17.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 OLIGONUCLEOTIDE CDMO MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS
  • TABLE 3 OLIGONUCLEOTIDE CDMO MARKET: PORTER'S FIVE FORCES
  • TABLE 4 OLIGONUCLEOTIDE CDMO MARKET: ROLE OF PLAYERS IN ECOSYSTEM
  • TABLE 5 OLIGONUCLEOTIDE CDMO MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026-JUNE 2027
  • TABLE 6 RECIPROCAL TARIFF RATES ADJUSTED BY US
  • TABLE 7 CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE CDMO MARKET
  • TABLE 8 CLIENTS' READINESS TO ADOPT AI-INTEGRATED OLIGONUCLEOTIDE CDMO TECHNOLOGIES IN OLIGONUCLEOTIDE CDMO MARKET
  • TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY SERVICE TYPE
  • TABLE 15 KEY BUYING CRITERIA, BY END USER
  • TABLE 16 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 17 OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 18 OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 19 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 20 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 21 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 22 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 23 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 24 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 25 OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 26 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 27 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 28 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 29 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 30 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 31 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 32 OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 33 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 34 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 35 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 36 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 37 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 38 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 39 OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 40 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 41 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 42 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 43 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 44 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 45 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 46 OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 47 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 48 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 49 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 50 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 51 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 52 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 53 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 54 OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 55 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 56 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 57 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 58 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 59 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 60 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 61 OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 62 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 63 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 64 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 65 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 66 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 67 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 68 OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 69 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 70 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 71 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 72 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 73 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 74 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 75 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 76 OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 77 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 78 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 79 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 80 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 81 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 82 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 83 OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 84 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 85 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 86 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 87 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 88 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 89 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 90 OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 91 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 92 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 93 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 94 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 95 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 96 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 97 OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 98 OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 99 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 100 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 101 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 102 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 103 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 104 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 105 OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 106 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 107 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 108 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 109 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 110 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 111 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 112 OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 113 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 114 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 116 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 117 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 118 GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 119 OLIGONUCLEOTIDE CDMO MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 120 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 121 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 122 NORTH AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 123 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 124 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 125 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 126 US: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 127 US: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 128 US: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 129 US: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 130 US: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 131 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 132 CANADA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 133 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 134 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 135 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 136 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 137 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 138 EUROPE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 139 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 140 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 141 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 142 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 143 GERMANY: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 144 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 145 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 146 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 147 UK: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 148 UK: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 149 UK: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 150 UK: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 151 UK: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 152 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 153 FRANCE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 154 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 155 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 156 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 157 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 158 ITALY: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 159 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 160 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 161 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 162 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 163 SPAIN: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 164 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 165 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 166 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 167 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 168 REST OF EUROPE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 169 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 170 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 171 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 172 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 173 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 174 ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 175 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 176 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 177 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 178 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 179 CHINA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 180 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 181 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 182 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 183 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 184 JAPAN: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 185 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 186 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 187 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 188 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 189 INDIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 190 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 191 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 192 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 193 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 194 AUSTRALIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 195 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 196 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 197 AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 198 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 199 SOUTH KOREA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 200 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 201 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 202 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 203 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 204 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 205 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 206 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 207 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 208 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 209 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 210 LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 211 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 212 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 213 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 214 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 215 BRAZIL: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 216 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 217 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 218 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 219 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 220 MEXICO: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 221 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 222 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 223 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 224 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 225 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 226 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 227 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 228 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 229 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 230 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 231 MIDDLE EAST: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 232 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 233 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 234 MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 235 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 236 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 237 GCC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 238 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 239 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 240 GCC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 241 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 242 SAUDI ARABIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 243 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 244 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 245 SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 246 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 247 UAE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 248 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 249 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 250 UAE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 251 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 252 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 253 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 254 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 255 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 256 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 257 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 258 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 259 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 260 REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 261 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 262 AFRICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
  • TABLE 263 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 264 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 265 AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 266 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE CDMO MARKET, 2023-2026
  • TABLE 267 OLIGONUCLEOTIDE CDMO MARKET: DEGREE OF COMPETITION
  • TABLE 268 OLIGONUCLEOTIDE CDMO MARKET: REGIONAL FOOTPRINT
  • TABLE 269 OLIGONUCLEOTIDE CDMO MARKET: SERVICE TYPE FOOTPRINT
  • TABLE 270 OLIGONUCLEOTIDE CDMO MARKET: TYPE FOOTPRINT
  • TABLE 271 OLIGONUCLEOTIDE CDMO MARKET: APPLICATION FOOTPRINT
  • TABLE 272 DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 273 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • TABLE 274 OLIGONUCLEOTIDE CDMO MARKET: SERVICE LAUNCHES, JANUARY 2023-JULY 2026
  • TABLE 275 OLIGONUCLEOTIDE CDMO MARKET: DEALS, JANUARY 2023-JULY 2026
  • TABLE 276 OLIGONUCLEOTIDE CDMO MARKET: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 277 BACHEM INC.: COMPANY OVERVIEW
  • TABLE 278 BACHEM INC.: SERVICES OFFERED
  • TABLE 279 BACHEM INC.: SERVICE LAUNCHES, JANUARY 2023-JULY 2026
  • TABLE 280 BACHEM INC.: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 281 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 282 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED
  • TABLE 283 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES, JANUARY 2023-JULY 2026
  • TABLE 284 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 285 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 286 AGILENT TECHNOLOGIES, INC.: SERVICES OFFERED
  • TABLE 287 AGILENT TECHNOLOGIES, INC.: SERVICE LAUNCHES, JANUARY 2023-JULY 2026
  • TABLE 288 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 289 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 290 WUXI APPTEC: COMPANY OVERVIEW
  • TABLE 291 WUXI APPTEC: SERVICES OFFERED
  • TABLE 292 WUXI APPTEC: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 293 MARAVAI LIFESCIENCES: COMPANY OVERVIEW
  • TABLE 294 MARAVAI LIFESCIENCES: SERVICES OFFERED
  • TABLE 295 MARAVAI LIFESCIENCES: DEALS, JANUARY 2023-JULY 2026
  • TABLE 296 LONZA: COMPANY OVERVIEW
  • TABLE 297 LONZA: SERVICES OFFERED
  • TABLE 298 LONZA: DEALS, JANUARY 2023-JULY 2026
  • TABLE 299 LONZA: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 300 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 301 EUROFINS SCIENTIFIC: SERVICES OFFERED
  • TABLE 302 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 303 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 304 DANAHER CORPORATION: SERVICES OFFERED
  • TABLE 305 DANAHER CORPORATION: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 306 DANAHER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2023-JULY 2026
  • TABLE 307 GENSCRIPT: COMPANY OVERVIEW
  • TABLE 308 GENSCRIPT: SERVICES OFFERED
  • TABLE 309 GENSCRIPT: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 310 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW
  • TABLE 311 SYNGENE INTERNATIONAL LIMITED: SERVICES OFFERED
  • TABLE 312 SYNGENE INTERNATIONAL LIMITED: SERVICE LAUNCHES, JANUARY 2023-JULY 2026
  • TABLE 313 SYNGENE INTERNATIONAL LIMITED: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 314 EUROAPI: COMPANY OVERVIEW
  • TABLE 315 EUROAPI: SERVICES OFFERED
  • TABLE 316 EUROAPI: DEALS, JANUARY 2023-JULY 2026
  • TABLE 317 EUROAPI: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 318 AJINOMOTO CO., INC.: COMPANY OVERVIEW
  • TABLE 319 AJINOMOTO CO., INC.: SERVICES OFFERED
  • TABLE 320 AJINOMOTO CO., INC.: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 321 AJINOMOTO CO., INC.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 322 ST PHARM: COMPANY OVERVIEW
  • TABLE 323 ST PHARM: SERVICES OFFERED
  • TABLE 324 ST PHARM: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 325 ST PHARM: DEALS, JANUARY 2023-JULY 2026
  • TABLE 326 KANEKA CORPORATION: COMPANY OVERVIEW
  • TABLE 327 KANEKA CORPORATION: SERVICES OFFERED
  • TABLE 328 POLYPEPTIDE GROUP: COMPANY OVERVIEW
  • TABLE 329 POLYPEPTIDE GROUP: SERVICES OFFERED
  • TABLE 330 POLYPEPTIDE GROUP: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 331 AURIGENE PHARMACEUTICAL SERVICES LTD.: COMPANY OVERVIEW
  • TABLE 332 AURIGENE PHARMACEUTICAL SERVICES LTD.: SERVICES OFFERED
  • TABLE 333 BIOSPRING: COMPANY OVERVIEW
  • TABLE 334 BIOSPRING: SERVICES OFFERED
  • TABLE 335 BIOSPRING: SERVICE APPROVALS, JANUARY 2023-JULY 2026
  • TABLE 336 BIOSPRING: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 337 NIPPON SHOKUBAI CO., LTD.: COMPANY OVERVIEW
  • TABLE 338 NIPPON SHOKUBAI CO., LTD.: SERVICES OFFERED
  • TABLE 339 NIPPON SHOKUBAI CO., LTD.: SERVICE LAUNCH, JANUARY 2023-JULY 2026
  • TABLE 340 NIPPON SHOKUBAI CO., LTD.: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 341 LGC BIOSEARCH TECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 342 LGC BIOSEARCH TECHNOLOGIES: SERVICES OFFERED
  • TABLE 343 LGC BIOSEARCH TECHNOLOGIES: SERVICE LAUNCH, JANUARY 2023-JULY 2026
  • TABLE 344 LGC BIOSEARCH TECHNOLOGIES: DEALS, JANUARY 2023-JULY 2026
  • TABLE 345 LGC BIOSEARCH TECHNOLOGIES: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 346 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 347 RISK ASSESSMENT

List of Figures

  • FIGURE 1 OLIGONUCLEOTIDE CDMO MARKET SEGMENTATION AND REGIONS CONSIDERED
  • FIGURE 2 OLIGONUCLEOTIDE CDMO MARKET: YEARS CONSIDERED
  • FIGURE 3 MARKET SCENARIO
  • FIGURE 4 GLOBAL OLIGONUCLEOTIDE CDMO MARKET, 2024-2031
  • FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE CDMO MARKET, 2023-2026
  • FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF OLIGONUCLEOTIDE CDMO MARKET
  • FIGURE 7 HIGH-GROWTH SEGMENTS IN OLIGONUCLEOTIDE CDMO MARKET, 2026-2031
  • FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN OLIGONUCLEOTIDE CDMO MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
  • FIGURE 9 INCREASING FOCUS ON PRECISION/PERSONALIZED MEDICINE
  • FIGURE 10 ANTISENSE OLIGONUCLEOTIDES ACCOUNTED FOR LARGEST SHARE OF OLIGONUCLEOTIDE CDMO MARKET IN NORTH AMERICA IN 2025
  • FIGURE 11 ASIA PACIFIC TO BE FASTEST-GROWING MARKET IN GLOBAL OLIGONUCLEOTIDE CDMO MARKET DURING FORECAST PERIOD
  • FIGURE 12 CONTRACT MANUFACTURING TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 13 OLIGONUCLEOTIDE CDMO MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 14 OLIGONUCLEOTIDE CDMO MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 15 VALUE CHAIN ANALYSIS
  • FIGURE 16 OLIGONUCLEOTIDE CDMO MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 17 OLIGONUCLEOTIDE CDMO MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 18 INVESTMENT AND FUNDING SCENARIO, 2023-2026 (USD MILLION)
  • FIGURE 19 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET
  • FIGURE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY SERVICE TYPE
  • FIGURE 21 KEY BUYING CRITERIA, BY END USER
  • FIGURE 22 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET SNAPSHOT
  • FIGURE 23 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET SNAPSHOT
  • FIGURE 24 REVENUE ANALYSIS FOR OLIGONUCLEOTIDE CDMO MARKET, 2021-2025
  • FIGURE 25 OLIGONUCLEOTIDE CDMO MARKET SHARE ANALYSIS, BY KEY PLAYER, 2025
  • FIGURE 26 OLIGONUCLEOTIDE CDMO MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2025
  • FIGURE 27 OLIGONUCLEOTIDE CDMO MARKET: COMPANY FOOTPRINT
  • FIGURE 28 OLIGONUCLEOTIDE CDMO MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2025
  • FIGURE 29 BRAND/PRODUCT COMPARATIVE ANALYSIS FOR OLIGONUCLEOTIDE CDMO MARKET, BY COMPANY
  • FIGURE 30 EV/EBITDA OF KEY VENDORS IN CDMO MARKET
  • FIGURE 31 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS IN OLIGONUCLEOTIDE CDMO MARKET
  • FIGURE 32 BACHEM INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 33 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 34 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 35 WUXI APPTEC: COMPANY SNAPSHOT (2025)
  • FIGURE 36 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2025)
  • FIGURE 37 LONZA: COMPANY SNAPSHOT (2025)
  • FIGURE 38 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025)
  • FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 40 GENSCRIPT: COMPANY SNAPSHOT (2025)
  • FIGURE 41 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2025)
  • FIGURE 42 EUROAPI: COMPANY SNAPSHOT (2025)
  • FIGURE 43 AJINOMOTO CO., INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 44 ST PHARM: COMPANY SNAPSHOT (2025)
  • FIGURE 45 KANEKA CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 46 POLYPEPTIDE GROUP: COMPANY SNAPSHOT (2025)
  • FIGURE 47 NIPPON SHOKUBAI CO., LTD.: COMPANY SNAPSHOT (2025)
  • FIGURE 48 LGC BIOSEARCH TECHNOLOGIES: COMPANY SNAPSHOT (2024)
  • FIGURE 49 OLIGONUCLEOTIDE CDMO MARKET: RESEARCH DESIGN
  • FIGURE 50 OLIGONUCLEOTIDE CDMO MARKET: BREAKDOWN OF PRIMARIES
  • FIGURE 51 OLIGONUCLEOTIDE CDMO MARKET: INSIGHTS FROM PRIMARIES
  • FIGURE 52 GLOBAL OLIGONUCLEOTIDE CDMO MARKET ESTIMATION, 2025
  • FIGURE 53 OLIGONUCLEOTIDE CDMO MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025)
  • FIGURE 54 ILLUSTRATIVE EXAMPLE OF AGILENT TECHNOLOGIES, INC.: REVENUE ANALYSIS (2025)
  • FIGURE 55 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 56 OLIGONUCLEOTIDE CDMO MARKET: CAGR PROJECTIONS
  • FIGURE 57 OLIGONUCLEOTIDE CDMO MARKET: DATA TRIANGULATION